Europe PMC
open access
Sialic acid <i>cis</i>-ligands as modulators of Siglec function in cancer immunity
The Siglec-sialoglycan axis is an emerging glyco-immune checkpoint in cancer. This is supported by the frequent upregulation of both Siglecs and sialoglycans in the tumor microenvironment. Siglecs are receptors expressed on immune cells that recognize sialoglycans, carbohydrate structures terminated
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Siglec-15 is a glyco-immune checkpoint in prostate cancer regulating immune evasion and metastasis#668726
- Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC#1321856
- Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors#1088261
- A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer#1432450
- T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive#1184474
Record · ID 1614438
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive